5-HTP and Creatine for Depression R33 Phase
Part of paid clinical trials in Salt Lake City, Utah.
- Sponsor
- University of Utah
- Study ID
- NCT05895747
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Low Dose 5-hydroxytryptophan — DRUG5-hydroxytryptophan 100mg PO BID
- High Dose 5-hydroxytryptophan — DRUG5-hydroxytryptophan 200mg PO BID
- Low Dose Creatine Monohydrate — DRUGCreatine monohydrate 5g PO qday
- High Dose Creatine Monohydrate — DRUGCreatine monohydrate 10g PO qday
- Placebo — DRUGCreatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study Details
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.
Key Dates
- Start date
- Sep 28, 2023
- Status verified
- Aug 2025
- Primary completion
- Jun 30, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 106 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Low Dose 5-hydroxytryptophan and Creatine Monohydrate5-HTP 100mg PO BID plus creatine 5g PO Qday
- Experimental: High Dose 5-hydroxytryptophan and Creatine Monohydrate5-HTP 200mg PO BID plus creatine 10mg PO Qday
- Placebo Comparator: Double PlaceboCreatine-matched placebo and 5-HTP-matched placebo
Primary Outcome Measure
17-Item Hamilton Depression Rating Scale [ Time Frame: 8 weeks ]
Central Contacts
- Brent Kious, MD8015851418
- Hailey Nielson, MS801-581-3475
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Utah Department of Psychiatry | Salt Lake City | Utah | 84108 |
Find similar trials in Salt Lake City, UT
By condition
By specialty
By research site
Related Studies
- Mechanisms of Rumination Change in Adolescent DepressionRecruiting · Ohio State University · Columbus, Ohio
- Study of ALTO-300 in MDDPHASE2 · Recruiting · Alto Neuroscience · Phoenix, Arizona
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPHASE2 · Recruiting · Syndeio Biosciences, Inc · Birmingham, Alabama
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"PHASE3 · Recruiting · Cybin IRL Limited · Phoenix, Arizona